Biological therapies for atopic dermatitis: An update

Area of Science:

• Dermatology and Immunology
• Pharmacology

Background:

• Severe atopic dermatitis is a chronic skin condition affecting adults and children, significantly reducing quality of life.
• Key features include skin barrier dysfunction and immune system dysregulation.
• Refractory cases often do not respond to conventional treatments.

Purpose of the Study:

• To review current and emerging biologic therapies for severe atopic dermatitis.
• To focus on novel targeted agents for managing this debilitating skin condition.

Main Methods:

• Literature review of systemic and topical biologic treatments.
• Analysis of targeted agents based on immunopathology.

Main Results:

• Identified systemic immunotherapies including Omalizumab, Dupilumab, Lebrikizumab, Tralokinumab, Nemolizumab, Ustekinumab, Fezakinumab, Tezepelumab, Apremilast, and allergen-specific immunotherapy.
• Included topical agents such as Tofacitinib and Crisaborole.

Conclusions:

• Understanding atopic dermatitis immunopathology has led to targeted biologic therapies.
• These novel agents represent promising treatment options for severe, refractory atopic dermatitis.